SAN DIEGO– DTx Pharma, Inc. (DTx), a privately-held California biotechnology company developing novel RNA-based therapeutics to treat the genetic drivers of disease, today announced the appointment of Dr. Michael Huang as its Chief Medical Officer. Dr. Huang will provide leadership and supervision for DTx Pharma’s pipeline of clinical development programs.
“We are excited to welcome Dr. Huang to DTx Pharma at this pivotal time in our evolution. His caliber as a leader and deep experience in building effective teams for biotechnology companies will be invaluable as we continue to advance our pipeline,” said Arthur T. Suckow, Co-Founder and Chief Executive Officer of DTx Pharma.
With extensive leadership experience in advancing drug candidates through all phases of clinical development, his contributions have led to marketing authorizations for numerous therapeutics including Potiga®, Zevalin®, Uceris®, Ruconest®, and Austedo®.
Prior to DTx Pharma, Dr. Huang held key leadership roles at AmMax Bio and Spruce Biosciences. Through his career, he has led programs in RNA therapeutics, biologics and small molecules from initial IND through clinical proof-of-concept, late-stage development and beyond. Dr. Huang has also been recognized for supporting successful financing and business-development activities. He is also the author of a multitude of peer-reviewed journal articles, abstracts, and scientific publications.
Dr. Huang holds a Bachelor of Science in molecular and cell biology from the University of California at Berkeley and received his medical degree from the Chicago Medical School.
“What DTx Pharma has built is truly unique and incredibly valuable,” said Dr. Huang. “The team has created an impressive platform to help patients with genetic diseases. I’m both thrilled and grateful to join the team’s journey to ensure we can address countless disease targets currently undruggable due to disease-causing genes.”
